Total Payments
$1.3M
2024 Payments
$59,530
Companies
27
Transactions
881
Payment Breakdown by Category
Other$376,747 (29.6%)
Consulting$363,761 (28.6%)
Research$318,451 (25.1%)
Travel$191,496 (15.1%)
Food & Beverage$20,303 (1.6%)
Education$23.37 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $374,664 | 149 | 29.5% |
| Consulting Fee | $363,761 | 71 | 28.6% |
| Unspecified | $318,451 | 79 | 25.1% |
| Travel and Lodging | $191,496 | 365 | 15.1% |
| Food and Beverage | $20,303 | 213 | 1.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,083 | 1 | 0.2% |
| Education | $23.37 | 3 | 0.0% |
Payments by Type
General
$952,330
802 transactions
Research
$318,451
79 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $317,449 | 214 | $0 (2024) |
| SANOFI US SERVICES INC. | $196,610 | 30 | $0 (2019) |
| Merck Sharp & Dohme LLC | $166,223 | 150 | $0 (2022) |
| Novo Nordisk Inc | $148,257 | 133 | $0 (2023) |
| Novo Nordisk AS | $110,806 | 49 | $0 (2018) |
| Lilly USA, LLC | $105,310 | 92 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $70,810 | 88 | $0 (2023) |
| Eli Lilly and Company | $56,408 | 15 | $0 (2024) |
| Pacira Pharmaceuticals Incorporated | $34,078 | 19 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $23,340 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,530 | 73 | Lilly USA, LLC ($56,296) |
| 2023 | $22,425 | 26 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,417) |
| 2022 | $62,754 | 40 | Pacira Pharmaceuticals Incorporated ($34,078) |
| 2021 | $32,337 | 21 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,355) |
| 2020 | $53,986 | 45 | Boehringer Ingelheim Pharmaceuticals, Inc. ($10,846) |
| 2019 | $264,452 | 145 | SANOFI US SERVICES INC. ($102,246) |
| 2018 | $247,538 | 214 | SANOFI-AVENTIS U.S. LLC ($100,368) |
| 2017 | $527,759 | 317 | SANOFI-AVENTIS U.S. LLC ($145,577) |
All Payment Transactions
881 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Obesity | ||||||
| 10/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Obesity | ||||||
| 10/25/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Obesity | ||||||
| 10/25/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Obesity | ||||||
| 10/23/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $6.96 | General |
| Category: Obesity | ||||||
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $994.88 | General |
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $608.70 | General |
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $223.22 | General |
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $196.38 | General |
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $173.28 | General |
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $154.42 | General |
| 10/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $138.97 | General |
| 10/22/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $98.74 | General |
| Category: Obesity | ||||||
| 10/17/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $75.26 | General |
| Category: Endocrinology | ||||||
| 09/11/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $80.22 | General |
| 06/22/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $116.00 | General |
| Category: Endocrinology | ||||||
| 06/22/2024 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological), SOLIQUA 100/33 | Food and Beverage | In-kind items and services | $36.64 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 05/29/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Obesity | ||||||
| 05/29/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Obesity | ||||||
| 05/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $367.48 | General |
| 05/24/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $116.26 | General |
| Category: Obesity | ||||||
| 05/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | — | Cash or cash equivalent | $721.50 | Research |
| Study: 22267 DMC Agreement - Helena Wachslicht Rodbard, MD • Category: Cardio-renal | ||||||
| 05/02/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Obesity | ||||||
| 05/02/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Obesity | ||||||
| 04/30/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: Obesity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Type 2 Diabetes Mellitus | SANOFI US SERVICES INC. | $92,925 | 6 |
| Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine | SANOFI US SERVICES INC. | $91,280 | 12 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $32,440 | 3 |
| Odyssey DM- Dyslipidemina | SANOFI-AVENTIS U.S. LLC | $25,836 | 2 |
| HOE901 | SANOFI-AVENTIS U.S. LLC | $15,333 | 3 |
| Efficacy & Safety vs Placebo | SANOFI-AVENTIS U.S. LLC | $10,636 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $9,308 | 2 |
| Efficacy & Safety vs Tresiba | SANOFI-AVENTIS U.S. LLC | $7,420 | 1 |
| Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 | SANOFI US SERVICES INC. | $6,665 | 2 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents | SANOFI-AVENTIS U.S. LLC | $6,000 | 1 |
| Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period | SANOFI US SERVICES INC. | $4,301 | 1 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $3,989 | 3 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $2,568 | 2 |
| A Pooled Analysis Evaluating the Effect of Sotagliflozin on Blood Pressure and Markers of Arterial Stiffness | SANOFI-AVENTIS U.S. LLC | $1,603 | 3 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers | SANOFI-AVENTIS U.S. LLC | $1,500 | 1 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Di | SANOFI US SERVICES INC. | $1,439 | 9 |
| inTandem1 and inTandem2 pooled analysis | SANOFI-AVENTIS U.S. LLC | $1,203 | 3 |
| Hypoglycemia Reduction with Sotagliflozin Despite improved HbA1c at 52 weeks: a Meta-analysis in Adults with Type 1 Diabetes | SANOFI-AVENTIS U.S. LLC | $1,020 | 3 |
| Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine | SANOFI-AVENTIS U.S. LLC | $886.45 | 10 |
| Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem1),Effic | SANOFI-AVENTIS U.S. LLC | $872.67 | 1 |
| 22267 DMC Agreement - Helena Wachslicht Rodbard, MD | Bayer Healthcare Pharmaceuticals Inc. | $721.50 | 1 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $276.67 | 5 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $227.14 | 2 |
About Dr. Helena Rodbard, M.D
Dr. Helena Rodbard, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Rockville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346260841.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Helena Rodbard, M.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $59,530 received in 2024. These payments were reported across 881 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($374,664).
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Rockville, MD
- Active Since 07/20/2006
- Last Updated 12/19/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1346260841
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $146,379
- JARDIANCE (Drug) $122,030
- SAR341402 (Drug) $102,246
- SOLIQUA (Drug) $92,396
- TOUJEO (Drug) $67,783
- Victoza (Drug) $63,726
- Ozempic (Drug) $56,757
- PRALUENT (Drug) $50,772
- FIASP (Drug) $48,255
- JANUVIA (Drug) $45,354
- ZEPBOUND (Drug) $43,027
- Tresiba (Drug) $34,578
- SOLIQUA 100/33 (Drug) $25,814
- STEGLATRO (Drug) $22,597
- SOTAGLIFLOZIN (Drug) $22,221
- Zilretta (Drug) $20,762
- FARXIGA (Drug) $11,771
- Kerendia (Drug) $11,410
- Exparel (Drug) $10,912
- QSYMIA (Drug) $6,856
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Rockville
Dr. David Brown, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $772,094
Endocrinology, Diabetes & Metabolism $772,094
Michael Dempsey, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $107,778
Endocrinology, Diabetes & Metabolism $107,778
Dr. Jie He, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $28,893
Endocrinology, Diabetes & Metabolism $28,893
Monika Mannan, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $7,501
Endocrinology, Diabetes & Metabolism $7,501
Linda Nguyen, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2,797
Endocrinology, Diabetes & Metabolism $2,797
Dr. Edward Movius, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $2,197
Endocrinology, Diabetes & Metabolism $2,197